We found that transient TUBB3 activation, through ABCB1, in response to the stimulation of FOXO3a expression, significantly contributes to the cross-resistance of the PTX-resistant cell population and consequently limits the efficacy of both agents where cancer cells have developed multiple resistance. Here, TUBB3 is linked to cancer.